{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:59:28Z","timestamp":1783742368811,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:00:00Z","timestamp":1505952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.nefro.2017.07.003","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T05:30:44Z","timestamp":1509946244000},"page":"197-206","source":"Crossref","is-referenced-by-count":8,"title":["Bloqueo del sistema renina-angiotensina-aldosterona en pacientes con enfermedad renal diab\u00e9tica avanzada"],"prefix":"10.1016","volume":"38","author":[{"given":"Sheila","family":"Bermejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles Oriol","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Mojal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2017.07.003_bib0155","unstructured":"Federaci\u00f3n ID. IDF Diabetes Atlas, 7.\u00aa ed. Bruselas, B\u00e9lgica: Federaci\u00f3n Internacional de Diabetes, 2015."},{"key":"10.1016\/j.nefro.2017.07.003_bib0160","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1523-1755.2004.00925.x","article-title":"Progression of nephropathy in type 2 diabetic patients","volume":"66","author":"Rossing","year":"2004","journal-title":"Kidney International"},{"key":"10.1016\/j.nefro.2017.07.003_bib0165","unstructured":"Registre de Malalts Renals Cr\u00f2nics de Catalunya. Informe estad\u00edstic 2014. Servei Catal\u00e0 de la Salut. Organitzaci\u00f3 Catalana de Trasplantaments (OCATT). Departament de Salut. Generalitat de Catalunya. 1.\u00aa edici\u00f3n. Junio 2016."},{"key":"10.1016\/j.nefro.2017.07.003_bib0170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2017.07.003_bib0175","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2017.07.003_bib0180","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2017.07.003_bib0185","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.nefro.2017.07.003_bib0190","first-page":"337","article-title":"KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","year":"2012","journal-title":"Kidney Int Suppl."},{"issue":"Suppl. 1","key":"10.1016\/j.nefro.2017.07.003_bib0195","first-page":"S4","article-title":"Standards of Medical Care in Diabetes 2015. American Diabetes Association","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nefro.2017.07.003_bib0200","article-title":"Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR<45mL\/min)","volume":"30","author":"Bilo","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2017.07.003_bib0205","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Aller","year":"2011","journal-title":"The New England Journal of medicine"},{"key":"10.1016\/j.nefro.2017.07.003_bib0210","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2017.07.003_bib0215","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2017.07.003_bib0220","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2017.07.003_bib0225","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2017.07.003_bib0230","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"2","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2017.07.003_bib0235","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/ndt\/gfr027","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"26","author":"Baweja","year":"2011","journal-title":"Nephrol. Dial. Transplant"},{"key":"10.1016\/j.nefro.2017.07.003_bib0240","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/ki.2012.18","article-title":"Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD","volume":"81","author":"Jain","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2017.07.003_bib0245","first-page":"229","article-title":"Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population","volume":"27","author":"Afghahi","year":"2013","journal-title":"JDC"},{"key":"10.1016\/j.nefro.2017.07.003_bib0250","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10157-015-1191-2","article-title":"Role of renin-angiotensin system inhibitors in retardation of progression of end-stage renal failure: a retrospective study","volume":"20","author":"Murakami","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefro.2017.07.003_bib0255","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1470320314550018","article-title":"Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study","volume":"16","author":"Tylicki","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.nefro.2017.07.003_bib0260","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/sj.ki.5000326","article-title":"Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL","volume":"69","author":"De Zeeuw","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2017.07.003_bib0265","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tem.2005.02.003","article-title":"The renin-angiotensin-aldosterone system, glucose metabolism and diabetes","volume":"16","author":"Giacchetti","year":"2005","journal-title":"Trends Endocrinol Metab."},{"key":"10.1016\/j.nefro.2017.07.003_bib0270","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2009","journal-title":"N Eng J Med"},{"key":"10.1016\/j.nefro.2017.07.003_bib0275","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archinte.1996.00440030080010","article-title":"Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: A 7-yearfollow-up study","volume":"156","author":"Ravid","year":"1996","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.nefro.2017.07.003_bib0280","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascularrisk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2017.07.003_bib0285","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/qjmed\/hcu105","article-title":"Age may explain the association of an early dialysis initiation with poor survival","volume":"107","author":"Soler","year":"2014","journal-title":"QJM."},{"key":"10.1016\/j.nefro.2017.07.003_bib0290","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/1470320313507122","article-title":"The effect of renin-angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia","volume":"15","author":"Lee","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.nefro.2017.07.003_bib0295","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.nefro.2017.07.003_bib0300","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699517301807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699517301807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T13:10:11Z","timestamp":1530018611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699517301807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0211699517301807"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2017.07.003","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}